Part II — Metabolic Peptides: The Revolution

Chapters 7–13

Something genuinely unusual happened in metabolic medicine, and it is worth being precise about what.

It is not that a weight-loss drug appeared. Weight-loss drugs have appeared regularly for a century, and the history is grim: amphetamines, fen-phen and its heart valves, sibutramine and its cardiovascular signal, rimonabant and its psychiatric one. The field's track record was so bad that serious pharmacologists had largely stopped believing a safe, effective, durable anti-obesity drug was achievable.

What happened is that a gut hormone turned out to be the answer, and it worked for reasons nobody fully anticipated, and then it kept working on things it had no business working on.

The arc of Part II

Chapter 7 starts with the biology, because the drugs make no sense without it. There is a system in your gut that senses food arriving and sends a chemical message ahead of it — a message that tells the pancreas to prepare insulin, tells the stomach to slow down, and tells the brain that food is here. That system is the incretin axis, GLP-1 is its most famous member, and its native form is destroyed within about two minutes of release. That fragility is why the system was a scientific curiosity for twenty years before it became a drug.

Chapter 8 is semaglutide in full: the three molecular modifications that solved the two-minute problem, the trial programs (SUSTAIN, STEP, PIONEER, SELECT), what the trials actually measured, what the headlines dropped, the adverse effects stated honestly, and the finding that reframed the entire drug class — weight returns when the drug stops. That single result is why this is chronic therapy rather than a course of treatment, and it is the most consequential thing in the chapter.

Chapter 9 covers what came next: tirzepatide, which hits two receptors with one molecule and produces larger effects; retatrutide, which hits three and is still in Phase 2; and the small-molecule compounds that may eventually make the injection unnecessary. It is also where the book's hardest statistical lesson lives, because one tirzepatide trial honestly reports two different weight-loss figures and popular coverage picks whichever is larger.

Chapter 10 is the strangest part of the story. A drug developed to lower blood sugar reduced cardiovascular events. Then kidney outcomes. Then, apparently, liver disease. Trials are running in Alzheimer's disease and in addiction. One molecule, five ratings — and the discipline of rating each indication separately is the skill this chapter exists to build.

Chapter 11 goes back a century to insulin, which is the correct comparison point for everything in this part. It is the original peptide drug, the most proven compound in this book, and a case study in something that has nothing to do with pharmacology: how a molecule that costs little to make came to cost a great deal to buy.

Chapter 12 is the fight. Price, insurance, shortage, compounding, telehealth, off-label prescribing, equity, and the genuinely unresolved argument about whether obesity is a disease, a behavior, or an environment. The book presents the full range of positions rather than picking one, and it is careful about a population these drugs can harm.

Chapter 13 widens the lens: amylin, the melanocortin pathway, leptin, PYY, ghrelin — the rest of the appetite system, most of which has failed as a drug target, and the reasons why illuminate what made GLP-1 different.

Why this part sets the standard for the rest of the book

Part II is where the evidence is best. Tens of thousands of trial participants, cardiovascular outcome trials with hard endpoints and years of follow-up, regulatory review in multiple jurisdictions, and post-marketing data from millions of prescriptions.

That matters for Parts III through VI, because it establishes what "good" looks like.

When Chapter 17 says that BPC-157 has no completed randomized human trials, that statement means something specific and comparable: it means the absence of the thing you will have just spent seven chapters watching semaglutide accumulate. Without Part II, "no human trials" is an abstraction. With it, you know exactly what is missing, and roughly how much work it would take to produce.

This part also contains the book's most important corrective. The GLP-1 drugs are genuinely remarkable, and remarkable is not the same as understood. We do not yet know what twenty years of continuous use does. We are still learning what happens to lean mass, to bone, to people who stop. The drugs are excellent and the story is unfinished, and Part II tries hard to hold both.

📋 Your Evidence Dossier — Part II

Chapter 8 gives you the model entry: all twelve fields, completed on one peptide, in full. Every other entry in your dossier should be measured against it.

Chapter 9 adds comparison discipline — two peptides, one indication, the same standard applied to both. Chapter 10 adds the rule that most often goes missing: one molecule can hold several different ratings at once, and collapsing them into a single verdict is how good drugs get oversold.

Chapters in This Part